Rest-Of-The-Asia-Pacific Mice Model Market Size, Share,Trends, Growth Analysis Report, 2030

Overview Request Sample Pages Request Customization Download PDF

You are viewing: Rest Of The Asia Pacific Mice Model Market analysis

Part of: Mice Model Market (Global)

The Rest Of The Asia Pacific Mice Model Market was valued at $23 Million in 2025 and projected to reach to $33.7 Million by 2030, representing a compound annual growth rate of 7.9%. Rest Of The Asia Pacific's mice model market is positioned for sustained growth as pharmaceutical companies increasingly establish research operations in the region.

Rest Of The Asia Pacific Mice Model Market (2025-2030) : Size and Share

CAGR of

USD Million

Rest Of The Asia Pacific Mice Model Market Trends and Insights

Rest Of The Asia Pacific represents a critical region for preclinical research and drug development, driven by expanding pharmaceutical and biotechnology sectors across emerging economies.
The region's growing investment in life sciences infrastructure and increasing adoption of genetically modified mouse models are propelling market expansion throughout the forecast period. Rest Of The Asia Pacific's mice model market benefits from rising R&D expenditures and heightened demand for disease modeling in oncology, neurology, and metabolic disorders.
Rest Of The Asia Pacific countries are increasingly establishing contract research organizations (CROs) and academic research institutions that rely on standardized mouse models for efficacy and safety testing.
This 7.9% compound annual growth rate reflects Rest Of The Asia Pacific's emerging position as a hub for translational research and its commitment to advancing precision medicine initiatives..

Key Market Statistics

CAGR (2025-2030) 7.9% CAGR
Market Size, 2025 ~USD 23 Million
Forecast, 2030 ~USD 33.7 Million
Country Rest Of The Asia Pacific

Rest Of The Asia Pacific Mice Model Market Overview

Market Valuation Growth :

Rest Of The Asia Pacific mice model market valued at $23.0 million in 2025, with projected growth to $33.7 million by 2030, representing a robust 7.9% CAGR over the forecast period.

Emerging Pharma & Biotech Expansion :

Rapid expansion of pharmaceutical and biotechnology sectors across emerging economies in the region is driving increased demand for preclinical research models and in vivo testing capabilities.

Life Sciences Infrastructure Investment :

Growing government and private sector investments in research facilities, academic institutions, and contract research organizations are establishing Rest Of The Asia Pacific as a key preclinical research hub.

Cost-Effective Research Advantage :

Lower operational costs compared to developed markets make Rest Of The Asia Pacific an attractive destination for outsourced preclinical studies and drug development programs.

Rest Of The Asia Pacific Mice Model Market Dynamics

The expanding biotech ecosystem, coupled with rising R&D investments from both multinational corporations and domestic players, is creating substantial demand for standardized mouse models and related services.
Regulatory harmonization efforts and improved laboratory standards are enhancing the region's credibility for preclinical research. The forecast period through 2030 will likely see accelerated adoption driven by cost advantages, growing disease prevalence requiring drug development, and increased collaboration between regional research institutions and global pharmaceutical firms.
Investment in specialized breeding facilities and genetically modified mouse models will further strengthen the market's competitive position within Asia Pacific..

Related Ecosystem

Biotechnology

Top Technologies

Reagents
Polymerase Chain Reaction (PCR)
Stem Cells
Assay Kits
Flow Cytometers

Top Companies

Thermo Fisher Scientific Inc.
Merck KGaA
Danaher Corporation
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.

Key Takeaways

Rest Of The Asia Pacific mice model market valued at $23.0M in 2025, expanding to $33.7M by 2030 at 7.9% CAGR
Rest Of The Asia Pacific's growth driven by increased pharmaceutical R&D investment and CRO establishment across emerging economies
Rest Of The Asia Pacific demand accelerating for genetically modified models in oncology, neurology, and metabolic disease research
Rest Of The Asia Pacific positioned as emerging translational research hub with strengthening life sciences infrastructure

Mice Model Market Report Scope

Report Metric	Details
Base Year	2025
Fastest Growing Segment	SERVICES (Model Type & Service)
Forecast Period	2025�2030
Growth Rate	CAGR of 10% from 2025 to 2030
Largest Segment	MODEL TYPE (Model Type & Service)
Market Size Base Year (Billions)	~USD 1.7 (2025)
Revenue Forecast (Billions)	~USD 2.74 (2030)
Segments Covered	Model Type & Service, Type, Technology, Application, Therapeutic Area, End User

Rest Of The Asia Pacific Mice Model Market Report Segmentation

6 segment dimensions are covered across the global market.

By Model Type & Service

Model Type
Services

By Type

Breeding Services
Cryopreservation Services
Genetically Engineered Mice
Hybrid/Congenic Mice
Inbred Mice
Other Services
Outbred Mice
Quarantine Services
Rederivation Services

By Technology

Crispr/Cas9
Embryonic Stem Cell Injections
Microinjections
Nuclear Transfer Technique
Other Technologies

By Application

Drug Discovery & Development
Personalized Medicine
Research Applications

By Therapeutic Area

Cardiovascular Diseases
Immunology
Metabolic Diseases
Neurology
Oncology
Other Therapeutic Areas

By End User

Academic & Research Institutes
Contract Research Organizations (Cros) & Contract Development And Manufacturing Organizations (Cdmos)
Pharmaceutical & Biotechnology Companies

Target Audience

Pharmaceutical Companies : Need regional market data to evaluate Rest Of The Asia Pacific for preclinical outsourcing, establish research partnerships, and optimize drug development timelines and budgets.
Biotechnology Firms : Require insights into local research capabilities, supplier networks, and regulatory requirements to expand preclinical operations and access cost-effective mouse model services.
Contract Research Organizations (CROs) : Seek market intelligence on demand trends, competitive positioning, and growth opportunities in Rest Of The Asia Pacific to expand service offerings and client acquisition.
Academic & Research Institutions : Need market data to secure funding, justify infrastructure investments, and benchmark their research capabilities against regional and global standards.
Investors & Private Equity : Require comprehensive market analysis to identify investment opportunities, assess growth potential, and evaluate acquisition targets in the Rest Of The Asia Pacific life sciences sector.

Key Companies in the Rest Of The Asia Pacific Mice Model Market

Company	HQ	Ownership	Strongest segments
HORIZON DISCOVERY GROUP PLC	United Kingdom	Private Company	Screening,Research Reagents,Diagnostics,
LABORATORY CORPORATION OF AMERICA HOLDINGS	United States	Public Company	Routine and wellness diagnostics (chemistry, hematology, urinalysis, wellness programs),Specialty and esoteric testing (gene-based, oncology, infectious disease, women�s health, pharmacogenetics),Biopharma Laboratory Services (clinical trial, central lab, medical device and diagnostic R&D),
CHARLES RIVER LABORATORIES	United States	Public Company	Discovery and Safety Assessment,Research Models and Services,Manufacturing Solutions,
THE JACKSON LABORATORY	United States	Foundation/Charitable Institution	Mouse breeding and colony management services,Cryopreservation, recovery, and genetic resource management,Phenotyping, efficacy testing, and study-ready induced models,
INOTIV	United States	Public Company	Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software,
JSR CORPORATION	Japan	Private Company	Digital Solutions (lithography, photoresists, packaging, CMP, display materials),Plastics (synthetic resins: ABS, AES, AS, ASA),Life Sciences (diagnostic reagents, bioprocess materials, drug discovery support),
BIOCYTOGEN	China	Public Company	Gene-Editing Services,Pharmacological Efficacy & Toxicology Services,Model Animals (Breeding & Sales),
SHANGHAI MODEL ORGANISMS CENTER, INC.	China	Public Company	Standard and disease mouse models (including toolbox and disease-specific strains),Customized genetically engineered models (KO, KI, humanized, transgenic),Preclinical services (non-GLP tox, PK, pharmacology/PD, phenotype analysis),
TRANS GENIC INC.	Japan	Public Company	Drug Discovery Support (non-clinical, bioequivalence, safety tests),Transgenic Models & Reagents (GM mice, antibodies, proteins, cells),Glycan Synthesis & Sugar Chain Analysis,
HARBOUR BIOMED	China	Public Company	Harbour Mice platform licensing and collaborations,Immunology clinical assets (e.g., batoclimab, HBM7020, HBM9378),Oncology clinical assets (e.g., porustobart, solid tumor portfolio),
GENOWAY	France	Public Company	Custom KO/KI mouse models,Custom KO/KI rat models,Humanized and immunodeficient rodent models (catalog and custom),
GEMPHARMATECH	China	Public Company	Standard GEMM catalog (knockout, conditional, knock-in, point-mutation, transgenic),Custom model generation and tool mice,Preclinical testing services,
VIVO BIO TECH LTD.	India	Public Company	In vivo and in vitro toxicity, PK/TK, and pharmacology services,SPF lab animals, rodent breeding, custom models, and lab diets,Genotoxicity screening and analytical services,

HORIZON DISCOVERY GROUP PLC

Horizon Discovery Group PLC is a United Kingdom-based private company founded in 2005 with 428 employees. The company operates in the life sciences sector, providing specialized research and development services.

LABORATORY CORPORATION OF AMERICA HOLDINGS

Laboratory Corporation of America Holdings is a major United States public company founded in 1995 with 66,385 employees. It is a leading provider of clinical laboratory services and drug development support.

CHARLES RIVER LABORATORIES

Charles River Laboratories is a United States public company founded in 1947 with 19,000 employees. The company provides preclinical and clinical laboratory services, research models, and safety assessment services.

THE JACKSON LABORATORY

The Jackson Laboratory is a United States foundation and charitable institution founded in 1929 with 2,100 employees. It is a premier research institution specializing in mammalian genetics and genomics.

INOTIV

Inotiv is a United States public company founded in 1974 with 1,996 employees. The company provides research models, services, and products for the pharmaceutical and biotechnology industries.

JSR CORPORATION

JSR Corporation is a Japan-based private company founded in 1948 with 7,997 employees. The company operates in advanced materials and life sciences sectors.

BIOCYTOGEN

Biocytogen is a China-based public company founded in 2008 with 1,443 employees. The company specializes in the development of genetically engineered animal models for research and drug development.

SHANGHAI MODEL ORGANISMS CENTER, INC.

Shanghai Model Organisms Center, Inc. is a China-based public company founded in 2000 with 848 employees. The company provides model organism services and products for biomedical research.

TRANS GENIC INC.

Trans Genic Inc. is a Japan-based public company founded in 1998 with 227 employees. The company develops and provides transgenic animal models for research applications.

HARBOUR BIOMED

Harbour Biomed is a China-based public company founded in 2016 with 272 employees. The company focuses on antibody and immunotherapy research and development.

GENOWAY

Genoway is a France-based public company founded in 1999 with 157 employees. The company specializes in the generation of genetically modified animal models for research.

GEMPHARMATECH

GemPharmatech is a China-based public company founded in 2017 with 1,590 employees. The company provides laboratory animal models and related research services.

VIVO BIO TECH LTD.

Vivo Bio Tech Ltd. is an India-based public company founded in 1987 with 174 employees. The company provides contract research services and laboratory animal models for pharmaceutical and biotechnology research.

Reasons to Buy this Report

Regional Market Sizing & Forecasts : Obtain precise valuation data specific to Rest Of The Asia Pacific ($23.0M in 2025, $33.7M in 2030) with country-level breakdowns to support investment decisions and market entry strategies.
Competitive Landscape Intelligence : Identify key players, suppliers, and service providers operating in Rest Of The Asia Pacific's mice model ecosystem to benchmark capabilities and partnership opportunities.
Growth Driver Analysis : Understand region-specific factors fueling 7.9% CAGR, including pharma expansion, infrastructure development, and regulatory trends unique to emerging Asia Pacific economies.
Strategic Expansion Planning : Leverage detailed market insights to evaluate Rest Of The Asia Pacific as a preclinical research outsourcing destination and identify high-potential sub-markets for business development.
Investment & Funding Opportunities : Access comprehensive data on market gaps, emerging segments, and growth catalysts to identify venture capital and M&A opportunities in the region's life sciences sector.

Frequently asked questions

What is the current market size of mice models in Rest Of The Asia Pacific?

Rest Of The Asia Pacific's mice model market was valued at $23.0 million in 2025 and is expected to grow to $33.7 million by 2030.

What is the projected growth rate for Rest Of The Asia Pacific mice model market?

Rest Of The Asia Pacific's mice model market is projected to grow at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2030.

Which therapeutic areas drive demand in Rest Of The Asia Pacific?

Rest Of The Asia Pacific sees strong demand for mice models in oncology, neurology, and metabolic disorder research, reflecting regional pharmaceutical priorities.

Why is Rest Of The Asia Pacific becoming important for mice model research?

Rest Of The Asia Pacific is emerging as a translational research hub due to expanding CRO networks, increased R&D investment, and growing adoption of genetically modified models.

What factors support market growth in Rest Of The Asia Pacific?

Rest Of The Asia Pacific's market growth is supported by rising pharmaceutical R&D expenditures, establishment of academic research institutions, and strengthening life sciences infrastructure.

RESEARCH METHODOLOGY

This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global mice model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include the International Mouse Phenotyping Consortium (IMPC), Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), European Molecular Biology Laboratory−European Bioinformatics Institute (EMBL-EBI), Swiss Laboratory Animal Science Association (SGV), Medical Research Council (MRC), Asian Mouse Mutagenesis Resource Association (AMMRA), Department of Biotechnology (DBT) (India), World Health Organization (WHO), United States Food and Drug Administration (US FDA), Annual Reports, SEC Filings, Investor Presentations, Research Journals, Press Releases, and financial statements. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative & quantitative information and assess the prospects of the market. Various primary sources from both the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate & validate the total size of the mice model market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Data Triangulation

The total market was split into several segments and subsegments after arriving at the overall market size from the estimation process. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

An animal model is a valuable resource in biomedical research, chosen for its ability to replicate certain aspects of biological processes or diseases observed in humans. A mouse model is a genetically engineered or naturally occurring mouse strain used in biomedical research to mimic human diseases or conditions. These models are valuable for their biological similarity to humans, ability to be genetically manipulated, and cost-effectiveness, enabling researchers to study disease mechanisms and test novel drug therapies efficiently. Mice share over 95% of human DNA and are biologically similar to humans, thereby being susceptible to similar diseases due to the genetic build-up.

Stakeholders

Manufacturers & Distributors of Mice Models
CROs & CDMOs
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Market Research & Consulting Firms
Researchers & Scientists
Regulatory Authorities & Institutes

Report Objectives

To define, describe, and forecast the global mice model market based on model type & service, technology, therapeutic area, application, product end user, service end user, and region
To provide detailed information regarding the leading factors driving the growth of the market (such as drivers, restraints, challenges, and opportunities)
To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall mice models market
To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
Track & analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the mice models market.
To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the mice model market.

Get the Full Mice Model Market Report

Full forecast, segment splits, and company analysis for all Mice Model Market.

Download Sample Pages Buy Report

REPORT COVERAGE

＋

Report Description
Market Overview
Market Dynamics
Related Ecosystem
Key Takeaways
Market Scope
Report Segmentation
Target Audience
Key Companies

Market Size in	USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered	Value (USD MN)